

## Hematological and Immunological reference intervals for adult population in the state of Amhara, Ethiopia

Bamlaku Enawgaw<sup>1</sup>, Wubet Birhan<sup>2</sup>, Molla Abebe<sup>3</sup>, Betelihem Terefe<sup>1</sup>, Habtamu Wondifraw Baynes<sup>3</sup>, Tekalign Deressa<sup>3</sup>, Mulugeta Melku<sup>1</sup>

<sup>1</sup>*Department of Hematology & Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia*

<sup>2</sup>*Department of Immunology & Molecular Biology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia*

<sup>3</sup>*Department of Clinical Chemistry, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia*

### ABSTRACT

**Objective:** Reference intervals (RIs) currently being used in Ethiopia are derived from western populations. Thus, this study aimed to establish locally derived hematological and immunological RIs.

**Method:** The study was conducted in Amhara State, Ethiopia with a total of 967 (55.2% males) participants. 56.9% of males and 43.1% of females were eligible for hematological and immunological RI determination. A non-parametric test was used for the determination of upper (97.5<sup>th</sup> percentile) and lower (2.5<sup>th</sup> percentile) reference interval limits with 95% CI. The Harris and Boyd Rule was used to determine the need of partitioning of reference intervals based on sex.

**Result:** The established 95% reference intervals (2.5<sup>th</sup> – 97.5<sup>th</sup> percentile) were: for WBC: 3 – 11.2 x10<sup>9</sup>/L; for platelet: 90 – 399 x10<sup>9</sup>/L; for RBC: 4 – 6 x10<sup>12</sup>/L for males and 3.5 – 5.6 x10<sup>12</sup>/L for females; for hemoglobin: (Hgb) 12 – 18.9g/dl for males and 10.7 – 17.5g/dl for females; for PCV: 35.7 – 55.3% for males and 32.2 – 50.1% for females; for CD4: 400 - 1430 x10<sup>9</sup>/L for males and 466 - 1523 x10<sup>9</sup>/L for females; for CD4 percentage: 18 – 49.1% for males and 21.3 – 52.9% for females; for MCV: 81 – 100fl; for MCH: 25.3 – 34.6pg; MCHC: 28.8 – 36.9%; for RDW: 11.6 – 15.4% and for MPV: 8 – 12.3fl. Males had significantly higher RBC, Hgb and PCV than females. CD4 counts and CD4 percentage were significantly higher in females.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/tmi.13071

This article is protected by copyright. All rights reserved.

**Conclusion:** The reference intervals established in this study differ from others and thus should be used for the interpretation of laboratory results in diagnosis and safety monitoring in clinical trials in Amhara.

**Keywords:** Reference interval, Hematological parameter, Immunological parameter, Amhara

## INTRODUCTION

Reference intervals (RIs) are also popularly known as reference ranges, normal values, normal ranges, biological reference intervals, and expected values (1). In clinical practice, before physiological assessments, medical diagnosis and management decisions are made, patient's laboratory results are compared with the corresponding reference intervals (RIs), which are bounded by a pair of reference limits (1, 2). RIs aid physicians in decision-making in clinical medicine to interpret results, in evaluating the state of health of individuals and populations, in identifying people at risk for disease, in assessing immune status, disease progression and treatment responses (3). They may also be used in clinical trials as a guide to setting inclusion or exclusion criteria and form the basis for safety monitoring of trial participants (4).

Laboratory parameters vary considerably between healthy people from different geographical locations, mostly driven by ethnic, genetic, demographic, nutritional, economic and environmental differences (5-10). Moreover, they vary from laboratory to laboratory due to differences among laboratories in clinical service needs, analytic platforms, set criteria to define populations of healthy individuals, analytic imprecisions made when RIs were determined, differences in methods used to establish RIs, techniques and timing of blood collection, subject's posture when the sample is taken, and physical activity of individuals (11-13).

Despite these differences, most African countries including Ethiopia use western population-derived laboratory RIs for clinical diagnosis and research activities. Studies conducted to evaluate and establish locally derived RIs in several African countries (6, 7, 14-22) revealed significant differences of locally derived RIs from those of currently used western population-derived RIs. This may lead to misclassification of patients that may result in misdiagnoses, improper treatments or both. Unless RIs are representative of the patient's demographics and determined using similar pre-analytical procedures and comparable analytical methods, they are inappropriate as a diagnostic reference for clinical decision-making.

Several factors affect hematological and immunological parameters. Therefore the Clinical Laboratory Standards Institute/International Federation for Clinical Chemistry (CLSI/IFCC) recommends that each laboratory establish RIs from the local population (5, 10, 12). Although some

Accepted Article  
attempts have been made to determine RIs in Ethiopia, they are fragmented and specific to small groups (14, 15), not comprehensive enough to be used in clinical practice (16, 22-24) and may lead to wrong interpretation (25). The RIs currently being used in Ethiopia are derived from Caucasian populations.

Therefore, we aimed to establish locally derived RIs of hematological and immunological parameters for adults in the state of Amhara, Ethiopia. This the first study in the country covering a large population.

## METHODS

### *Study setting and design*

This was a cross-sectional study of 1,040 blood donors in the Amhara blood bank districts of Gondar, Bahirdar, Debre Markos and Dessie to determine hematological and immunological RIs. Amhara (9° to 13° 45' N and 36° to 40° 30'E; 500 – 4,620 m asl, 159,173.66 km<sup>2</sup>) comprises hot dry tropical, sub-tropical, temperate and alpine climatic zones. In 2007 Amhara had a population of 17.2 million; 51.9% of the Ethiopian population were aged 15 – 64 years and and 45% were children <15 years (26).

### *Selection of reference population*

We used a convenience sampling technique to select the reference population during blood donation. Each blood bank has a fixed blood collection center and mobile blood collection sites. The mobile blood collection teams campaign in the community and collect blood from volunteers. The objective of the study was explained to the donors and informed consent taken. Volunteers' general good health was assessed through a medical history and physical examination. Donors were screened for infectious diseases by the Ethiopian blood bank service after blood donation. We excluded individuals known to have diabetes mellitus, chronic renal insufficiency, hypertension, ischemic heart disease, anemia, thyroid or liver disease; those taking pharmacologically active substances or any prescription drugs; smokers; individuals who had malaria in the previous 3 months, individuals who had jaundice or major surgery in the past year; pregnant (determined clinically or by urine HCG test) and lactating women; individuals who had donated blood in the previous 4 months and those who had received a blood transfusion in the previous year. Serum blood samples were screened for HIV, Hepatitis B virus, Hepatitis C virus and syphilis using ELISA techniques at each blood bank center.

### ***Laboratory analysis***

Four ml of blood were collected from the antecubital vein into a K3EDTA vacutainer tube for CD4 and complete blood count. A three-part differential complete blood count (CBC) was analyzed using CELL-DYN® 1800 (Abbott Laboratories Diagnostic Division, USA) at each blood bank center. We used diluent, detergent and CN-free diff lyse CELL-DYN reagents supplied by Abbott Laboratories Diagnostic Division. The analyzer used electrical impedance to count and size blood cells and the methemoglobin method for determination of Hgb, based on the measurement of changes in electrical resistance produced by cells suspended in conductive diluents as they pass through an aperture of known dimensions. As each cell passes through the aperture, a transitory change in the resistance between the electrodes occurs, producing a measurable electrical pulse. The number of pulses generated indicates the number of cells and the amplitude of each pulse is proportional to cell volume. In this manner cells are counted and classified into white blood cells (WBC), red blood cells (RBC) and platelets. Hemoglobin (Hgb), packed cell volume (PCV), absolute and relative number of lymphocytes, neutrophils and mixed cells (basophils, monocytes, eosinophils), mean cell volume (MCV), mean cell hemoglobin (MCH) and mean cell hemoglobin concentration (MCHC) were analyzed.

CD4 cell counts and CD4 percentages were determined using a Becton Dickinson Fluorescence Activated Cell Sorting (BD FACS) Count™ system (Becton Dickinson, San Jose, CA, USA), which provides reproducible and accurate results even with low CD4 counts and is widely used for CD4 monitoring in HIV/AIDS treatment programs. BD FACS Count reagents are provided as complete kits that streamline CD4 counting. These kits contain ready-to-use tubes with pre-measured antibodies and beads for absolute counting, fixative solution, and software that enables automated analysis without operator intervention. The beads and lymphocytes of interest are automatically identified and absolute counts (cells/ $\mu$ L) and percentages calculated. Quality controls in the software detect and flag error conditions and suppress results when control limits are exceeded.

### ***Quality Control***

Protocols for sample collection, processing and transportation were strictly followed to have safe procedures and reliable specimens. Samples were analyzed in batches within two hours of collection and delayed samples were kept at 2 – 8°C for a maximum of 12 hours. During analysis, both internal and external quality assurance (QA) protocols were followed. As an internal QA, commercial quality control samples were included in every batch. Test samples were run if and only if quality control samples were within range. For hematology tests three levels of whole blood controls (High, Medium, and Low) and for CD4 cell count, two levels of whole blood controls (Low, Normal) were

used. All analytes were analyzed by following standard operational procedures. As an external QA, the laboratory received quality control samples from the central laboratory, analyzed them as a patient sample and returned them to the center. The central laboratory then analyzed the data and gave performance evaluation feedback to each laboratory. The central laboratory received QA materials from UK and Canada.

### **Statistical Analysis**

Data were checked for completeness, cleaned, edited and entered into Epi-Info version 3.5.1 and then transported to SPSS v. 20 for statistical analysis. Outliers within each subgroup were identified using the Dixon and Reed method, namely the D/R ratio, where *D* is the absolute difference between an extreme observation (large or small) and the next largest (or smallest) observation, and *R* is the range (maximum – minimum). Extreme values were deleted from the distribution if  $D/R \geq 1/3$  (5). RIs were calculated according to the guideline of the Clinical Laboratory Standards Institute/International Federation for Clinical Chemistry (CLSI/IFCC) by employing a nonparametric method to determine the median interquartile ranges (IQR), combined or separate 95% RIs (2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles). The 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles were considered as lower and upper reference limits, respectively, covering 95% of the reference interval of each parameter (5). RIs were determined separately for males, females and combined sexes. To determine combined or separate sex RIs, the Harris and Boyd test was used as described below (27, 28):

$$Z = \frac{\text{Mean 1} - \text{Mean 2}}{(SD1/N1 + SD2/N2)^{1/2}}$$

where SD is standard deviation and N is the number of samples of each sex. This statistical Z result was compared with a critical Z\* value:

$$Z^* = 3[(N1 + N2)/240]^{1/2}$$

Separate RI was determined when  $Z > Z^*$ . Based on this test, separate-sex RIs were determined for RBC, Hgb, PCV, CD4 and CD4 percentages (Table 1).

### **Ethics**

This study was approved by the Research Review Board of University of Gondar and permission was obtained from the blood banks. Written informed consent was obtained from each participant. The study participants were informed about the aim of the study and its procedure, and inclusion was voluntary. Confidentiality was kept and withdrawal was possible at any stage.

## RESULTS

We enrolled 1,040 volunteer blood donors aged 18-61 years. 55.4% were male and 44.6% female. Of the total, 967 (55.2% males and 44.8% females) were eligible for hematological RI determination and 784 (56.9% males and 43.1% females) were eligible for immunological RI determination. The median age of study participants was 20 years with an IQR of 5 years. 80% were students aged 18-25 years.

The median and 95% reference intervals (2.5<sup>th</sup> – 97.5<sup>th</sup> percentiles) for hematological and immunological parameters are shown in Table 2. The combined median and 95<sup>th</sup> percentile for both sexes were as follows: 6.1 (3 – 11.2 x10<sup>9</sup>/L) for WBC, 3.2 (1.1 – 6.7 x10<sup>9</sup>/L) for absolute neutrophils, 2.1 (1.1 – 4.5 x10<sup>9</sup>/L) for absolute lymphocytes, 0.7 (0.2 – 2.1 x10<sup>9</sup>/L) for absolute mixed cells, 239 (90 – 399 x10<sup>9</sup>/L) for platelet, 90.1 (81 – 100fl) for MCV, 30 (25.3 – 34.6pg) for MCH, 33.9 (28.8 – 36.9%) for MCHC, 13.2 (11.6 – 15.4%) for RDW and 10 (8 – 12.3fl) for MPV for both sexes.

The separate RIs for males were: 5.1 (4 – 6 x10<sup>12</sup>/L) for RBC, 15.3 (12 – 18.9g/dl) for Hgb, 46.2 (35.7 – 55.3%) for PCV, 721 (400 - 1430 x10<sup>9</sup>/L) for CD4 and 36.3 (18 – 49.1%) for CD4 percentage. RIs for females were 4.5 (3.5 – 5.6 x10<sup>12</sup>/L) for RBC, 13.1 (10.7 – 17.5g/dl) for Hgb, 39.9 (32.2 – 50.1%) for PCV, 830 (466 - 1523 x10<sup>9</sup>/L) for CD4 and 40.3 (21.3 – 52.9%) for CD4 percentage. Males had significantly higher RBC, Hgb and PCV than females, whereas CD4 counts and CD4 percentages were significantly higher in females. The distribution of these variations with sex are expressed in Box and Whisker plots (Figure 1).

## DISCUSSION

Local RIs are recommended to be established and used for interpretation of laboratory results during screening, diagnosis and monitoring of patients and to assure the health status of individuals involved in clinical trials (4-6, 12). The RIs derived in this study varied from those reported in other areas (6, 14, 15, 29-31) and in text books (12, 32-34), as would be expected for populations in other geographical locations, with genetic and dietary diversities (5). As indicated in Table 3, the lower RI limit of total WBC count in this study was lower than previously reported from different parts of Ethiopia (14, 15), Eastern and Southern Africa (6), Western Kenya (7), Ghana (29), USA (30) and Caucasian populations (12, 32, 33); but it was higher than in Kericho district of Kenya (31), Togo (35) and Uganda (4). The WBC RI for this study is in agreement with southern Tanzania's (36) RI lower limit, whereas our upper RI limit was lower than in Gojjam district of Ethiopia (15), in books (32, 33) but higher than reported from Africa (4, 6, 7, 14, 31, 35), USA (30) and in text books (12, 34). Similarly the absolute neutrophil and lymphocyte count RI upper limits are higher than in most African countries RIs (4, 6, 7, 14, 31, 35) but lower than in Caucasian populations (12, 30, 34). These variations are usually associated with well-known differences in altitude, environment, diet, and

ethnic background (5). There was no significant difference in WBC count between males and females, confirming results of other studies (6, 14, 15, 29-31).

The 95<sup>th</sup> percentile RIs of our lower limit RI of RBC in both sexes were lower than those in Kenya (7, 31), Tanzania (36), USA (30) and western text books (32, 34) and higher than in previous studies in Gondar, Ethiopia (14), Ghana (29), Togo (35) and Uganda (4). The upper limit RI was lower than previous studies in Ethiopia (14, 15), Togo (35) but higher than in Ghana (29), USA (30) and in western books (32, 34). The differences might be due to geographical variation (altitude), environment, diet, ethnic background, method and instrument used for analysis (CLSI) (5, 17).

The lower limit of Hgb and PCV RIs in this study was lower than in Gojjam (15), Tanzania (36) and the USA (30), but higher than in Eastern and Western Africa (6), Ghana (29), Western Kenya (7), Togo (35) and Uganda (4) for both sexes. The upper limit of Hgb was higher than in Eastern and Western Africa (6), Ghana (29), Kenya (7, 31), Togo (35), Uganda (4), USA (30) but lower than in Gojjam (15), probably due to altitude and ethnic variations (5, 37, 38). Thus it may not be possible to even have one standard reference between two localities in the same county, as seen in Ethiopia and Kenya (7, 14, 15, 31).

The reference intervals of MCV, MCH and MCHC in this study varied from those of other studies (Table 3). Generally the RI of MCV is higher than in other African countries (4, 6, 7, 29, 31, 36) and comparable with Togo (35), USA (30) and values in text books (34). MCH and MCHC values showed variable results and RDW RIs are comparable with other studies (30, 34).

We observed a significant sex difference on red cell parameters (RBC, Hgb and PCV). Higher values were seen in males than females, confirming previous findings (12, 32-34) in Ethiopia (14, 15), Eastern and South Africa (6), Ghana (29), Kenya (7, 31), South Tanzania (36), Togo (35), Uganda (4) and USA (30). The significant differences between men and women in RBC, Hgb and PCV may be due to biological and physiological factors such as the influence of androgen hormone on erythropoiesis (39) and menstrual blood loss in females (40).

The RIs of platelets in this study were lower than in Gondar (14), Eastern and Southern Africa (6), Kenya (7, 31), Togo (35) and Caucasian populations (32, 34). However, the RI values are higher than Ghana (29). This may be associated with high altitude in Ethiopia, as platelet count decreases and mean platelet volume (MPV) increases with altitude (41-43).

CD4 RI determination is also important because CD4 lymphocyte cells are used for assessment of immune status, disease progression and treatment responses of patients, especially individuals living with HIV (3, 44). CD4 cell counts were higher than in Addis Ababa (16), Tanzania (21) and Central African Republic (20); but lower than in Gojjam, Ethiopia (15), Gauteng, South Africa (45) and Turkey (46). CD4 percentages RI in this study were generally lower than in other countries (7, 16, 45,

46), possibly due to ethnic and environmental factors (47, 48). There was a significant sex difference in absolute CD4 cells and CD4 percentages. The higher values seen in women in our study are consistent with other studies (7, 15, 16, 19, 20, 45) and may be due to the effect of sex hormones (49).

One limitation of our study is that the majority of the reference population included were young adults. Secondly, we did not screen the reference population for infectious diseases such as intestinal parasites.

## **CONCLUSION**

The reference values we established for the state of Amhara, Ethiopia will be helpful for the screening, diagnosis, monitoring and follow-up of patients. This study provides the first hematological and immunological RIs for a larger population in the state of Amhara, Ethiopia, and is the largest in the country. The RIs generated in Amhara differ from others in Africa and western countries. The WBC RI showed a wider range, with lower and upper RI limits showing variations from previous studies. Similarly, RBC parameters (RBC, Hgb and PCV), showed a slightly higher upper RI limit, whereas platelet counts, absolute CD4 counts and CD4 percentages gave lower RIs in this study. Thus the use of western RIs could lead to wrong diagnosis and interpretation of laboratory results. It is also advisable to establish RIs for the younger and older populations, giving due consideration to the effect of infectious diseases on hematological and immunological parameters.

## **Acknowledgements**

The authors would like to thank the study participants for volunteering to participate in this study; the staff of the Gondar, Bahirdar, Debre Markos and Dessie Blood Banks for their support during data collection and infectious disease screening; the University of Gondar hospital, Amhara Public Health Institute Laboratory, Debre Markos Hospital and Dessie Referral Hospital Laboratory staff who supported for hematological and CD4 laboratory analysis; and the University of Gondar for funding the project. The datasets during and/or analyzed during the current study available from the corresponding author upon request.



## REFERENCES

1. Solberg HE. Establishment and use of reference values. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz fundamentals of clinical chemistry. 6th ed. Philadelphia: Saunders; 2008. p. 232.
2. Friedberg RC, Souers R, Wagar EA, Stankovic AK, Valenstein PN, Pathologists CoA. The origin of reference intervals. Archives of pathology & laboratory medicine. 2007;131(3):348-57. Epub 2007/05/23.
3. Embree J, Bwayo J, Nagelkerke N, Njenga S NP, Ndinya-Achola J, Pamba H, et al. Lymphocyte subsets in human immunodeficiency virus type 1-infected and uninfected children in Nairobi. *Pediatr Infect Dis J*. 2001;20(4):397-403.
4. Eller LA, Eller MA, Ouma B, Kataaha P, Kyabaggu D, Richard Tumusiime, et al. Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials. *PLoS ONE*. 2008;3(12):e3919.
5. CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline-Third Edition. CLSI document EP28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
6. Karita E, Ketter N, Price MA, Kayitenkore K, Kaleebu P, Nanvubya A, et al. CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. *PloS one*. 2009;4(2):e4401.
7. Zeh C, Amornkul PN, Inzaule S, Ondoa P, Oyaro B, Mwaengo DM, et al. Population-based biochemistry, immunologic and hematological reference values for adolescents and young adults in a rural population in Western Kenya. *PloS one*. 2011;6(6):e21040.
8. Paul S. Horn, Amadeo J. Pesce. Effect of Ethnicity on Reference Intervals. *Clin Chem*. 2002;48(10):1802-4.
9. Siqués P, Brito J, León-Velarde F, Barrios L, De La Cruz JJ, López V, et al. Hematological and Lipid Profile Changes in Sea-Level Natives after Exposure to 3550-m Altitude for 8 Months. *High altitude medicine & biology*. 2007 8(4):286 -95.
10. PetitClerc C, Solberg HE. Approved recommendation on the theory of reference values (1987). Part 2. Selection of individuals for the production of reference values. *J Clin Chem Clin Biochem*. 1987;25(9):639-44.
11. Howanitz PJ, GS. C. Postanalytical quality improvement: a College of American Pathologists Q-Probes study of elevated calcium results in 525 institutions. *Arch Pathol Lab Med* 2000;124:504-10.
12. Bates I, Lewis SM. Reference ranges and normal values. In: Bain BJ, Bates I, Laffan MA, Lewis SM, editors. *Dacie and Lewis Practical Haematology*. 11th ed. London: Churchill Livingstone: Elsevier;

2011. p. 14.
13. Arneson W, Brickell J, Crellin M, Cavagnaro M. Clinical chemistry a laboratory perspective: Quality Assessment. Philadelphia, PA, USA.: F. A. Davis Company; 2007.
  14. Yalew A, Terefe B, Alem M, Enawgaw B. Hematological reference intervals determination in adults at Gondar university hospital, Northwest Ethiopia. BMC research notes. 2016;9(1):483. Epub 2016/11/04.
  15. Mulu W, Abera B, Mekonnen Z, Adem Y, Yimer M, Zenebe Y, et al. Haematological and CD4+ T cells reference ranges in healthy adult populations in Gojjam zones in Amhara region, Ethiopia. PLoS One. 2017;12(7):e0181268. Epub 2017/07/21.
  16. Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlun T, Doorly R, et al. Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab Immunol. 1999;6(3):410–114.
  17. Aneke C Nduka N, Maxwell-Owhochuku S. Comparison of some haematological indices of Africans and Caucasians resident in the Nigerian environment. Haematologia (Budapest). 1988;21(1):57-63.
  18. Klose N, Coulibaly B, Tebit D, Nauwelaers F, Spengler H, Kynast-Wolf G, et al. Immunohematological reference values for healthy adults in Burkina Faso. Clinical and Vaccine Immunology. 2007;14(6):782-4.
  19. Lugada Es, Mermin J, Kaharuzza F, Ulvestad E, Were W, Langeland N, et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clinical and Diagnostic Laboratory Immunology. 2004;11(1):29-34.
  20. Menard D, Mandeng MJ, Tothy MB, Kelembho EK, Gresenguet G, Talarmin A. Immunohematological reference ranges for adults from the Central African Republic. Clin Diagn Lab Immunol. 2003;10(3):443-5.
  21. Ngowi BJ, Mfinanga SG, Bruun JN, Morkve O. Immunohaematological reference values in human immunodeficiency virus-negative adolescent and adults in rural northern Tanzania. BMC Infectious Diseases. 2009;9:1.
  22. Gelaye B, Bekele T, Khali A, Haddis Y, Lemma S, Berhane Y, et al. Laboratory reference values of complete blood count for apparently healthy adults in Ethiopia. Clinical laboratory. 2011;57(7-8):635-40. Epub 2011/09/06.
  23. Gize A, Mathewos B, Moges B, Workineh M, Gedefaw L. Establishment of Normal Reference Intervals for CD3(+), CD4(+), CD8(+), and CD4(+) to CD8(+) Ratio of T Lymphocytes in HIV Negative Adults from University of Gondar Hospital, North West Ethiopia. AIDS research and treatment. 2014;2014:267450. Epub 2014/12/09.
  24. Kassu A, Tsegaye A, Petros B, Wolday D, Hailu E, Tilahun T, et al. Distribution of lymphocyte

- subsets in healthy human immunodeficiency virus-negative adult Ethiopians from two geographic locales. *Clin Diagn Lab Immunol*. 2001;8(6):1171-6. Epub 2001/11/01.
25. Haileamlak A, Muluneh AT, Alemseged F, Tessema F, Woldemichael K, Asefa M, et al. Hematoimmunological profile at gilgel gibe field research center, southwest ethiopia. *Ethiopian journal of health sciences*. 2012;22(S):39-50. Epub 2013/01/16.
26. Federal Democratic Republic of Ethiopia Population Census Commission. Summary and statistical report of the 2007 population and housing census. Population size by age and sex. 2008. Available at: <https://www.scribd.com/doc/28289334/Summary-and-Statistical-Report-of-the-2007>; Access on September 1, 2017.
27. Harris EK, Boyd JC. On dividing reference data into subgroups to produce separate reference ranges. *CLIN CHEM*. 1990;36(2):265-70.
28. Harris EK, Wong ET, Shaw ST. Statistical Criteria for Separate Reference Intervals: Race and Gender Groups in Creatine Kinase. *Clin Chem*. 1991;37(9):1580-2.
29. Dosoo DK, Kayan K, Adu-Gyasi D, Kwara E, Ocran J, Osei- K, et al. Haematological and Biochemical Reference Values for Healthy Adults in the Middle Belt of Ghana. *PLoS ONE*. 2012;7(4):e36308.
30. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the massachusetts general hospital: Laboratory Reference Values. *The New England journal of medicine*. 2004;351:1548-63.
31. Kibaya RS, Bautista CT, Sawe FK, Shaffer DN, Saterren WB, Scott PT, et al. Reference Ranges for the Clinical Laboratory Derived from a Rural Population in Kericho, Kenya. *PLoS ONE*. 2008;3(10):e3327.
32. Turgeon ML. *Clinical Hematology Theory and Procedures*. 5 ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.
33. Rodak BF, Fritsma GA, Keohane EM. *Hematology: Clinical principles and applications*. 4 ed. St. Louis, Missouri: Elsevier Saunders; 2011.
34. Keohane EM, Smith LJ, Walenga JM. *Rodak's Hematology: Clinical principles and applications*. 4 ed. St. Louis, Missouri: Elsevier Saunders; 2016.
35. Kueviakoe IM, Segbena AY, Jouault H, Vovor A, Imbert M. Hematological reference values for healthy adults in Togo. *ISRN Hematology*. 2011;2011.
36. Saathoff E, Schneider P, Kleinfeldt V, Geis S, Haule D, Maboko L, et al. Laboratory reference values for healthy adults from southern Tanzania. *Tropical Medicine and International Health*. 2008;13(5):612-25.
37. Kaya H, Kiki I, Akarsu E, Gundogdu M, Basol Tekin S, Inandi T. Hematological Values of Healthy

- Adult Population Living at Moderate Altitude (1869 m, Erzurum, Turkey). Turkish journal of haematology : official journal of Turkish Society of Haematology. 2000;17(3):123-8. Epub 2000/09/05.
38. Al-Sweedan SA, Alhaj M. The effect of low altitude on blood count parameters. Hematology/oncology and stem cell therapy. 2012;5(3):158-61. Epub 2012/10/26.
39. Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014;69(6):725-35.
40. Kim I, Yetley EA, Calvo MS. Variations in iron-status measures during the menstrual cycle. Am J Clin Nutr. 1993;58:705-9.
41. Vij AG. Effect of prolonged stay at high altitude on platelet aggregation and fibrinogen levels. Platelets. 2009;20(6):421-7. Epub 2009/08/07.
42. Hartmann S, Krafft A, Huch R, Breymann C. Effect of altitude on thrombopoietin and the platelet count in healthy volunteers. Thrombosis and haemostasis. 2005;93(1):115-7. Epub 2005/01/05.
43. Hudson JG, Bowen AL, Navia P, Rios-Dalenz J, Pollard AJ, Williams D, et al. The effect of high altitude on platelet counts, thrombopoietin and erythropoietin levels in young Bolivian airmen visiting the Andes. International journal of biometeorology. 1999;43(2):85-90. Epub 1999/11/07.
44. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. The New England journal of medicine. 1996;334(7):426-31. Epub 1996/02/15.
45. Lawrie D, Coetzee LM, Becker P, Mahlangu J, Stevens W, Glencross DK. Local reference ranges for full blood count and CD4 lymphocyte count testing. S Afr Med J. 2009;99:243-8.
46. Yaman A, Çetiner S, Kibar F, Tasova Y, Seydaoglu G, Dündar IH. Reference Ranges of Lymphocyte Subsets of Healthy Adults in Turkey. Med Princ Pract. 2005;14:189–93.
47. Moreno-Galvan M, Palafox A. CD4+ CD8+ T cell reference values in the Mexico City population. Clinical and vaccine immunology : CVI. 2013;20(2):306-8. Epub 2012/12/15.
48. Choong ML, Ton SH, Cheong SK. Influence of race, age and sex on the lymphocyte subsets in peripheral blood of healthy Malaysian adults. Annals of clinical biochemistry. 1995;32 ( Pt 6):532-9. Epub 1995/11/01.
49. Pernis AB. Estrogen and CD4+ T cells. Current opinion in rheumatology. 2007;19(5):414-20. Epub 2007/09/01.

**Correspondence:** Bamlaku Enawgaw, Department of Hematology & Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. Email: bamlak21@gmail.com

### Figure legend

**Figure 1.** Box and whisker plots indicating the effect of sex on hematological and immunological parameters of the study participants. **a:** Red blood cells, **b:** Hemoglobin, **c:** Packed Cell Volume, **d:** CD4 Counts and **e:** CD4 %

**Table 1:** Result of Harris and Boyd test, which was performed to see the need for partitioning of Reference interval based on sex

Parameters	Harris and Boyd		Decision
	Z*	Z	
WBC ( $\times 10^9/L$ )	6.0	0.7	No separate RI
Neutrophil ( $\times 10^9/L$ )	6.0	1.1	No separate RI
Lymphocyte ( $\times 10^9/L$ )	6.0	0.1	No separate RI
Mixed cells ( $\times 10^9/L$ )	6.0	0.6	No separate RI
Neutrophil (%)	6.0	1.2	No separate RI
Lymphocyte (%)	6.0	0.3	No separate RI
Mixed cells %	6.0	2.0	No separate RI
Platelet ( $\times 10^9/l$ )	6.0	3.3	No separate RI
RBC ( $\times 10^{12}/L$ ) **	6.0	18.6	Separate RI
Hgb (g/dl)**	6.0	16.7	Separate RI
PCV (%) **	6.0	19	Separate RI

MCH (pg)	6.0	1.3	No separate RI
MCHC (g/dl)	6.0	0.6	No separate RI
MCV (fl)	6.0	1.7	No separate RI
RDWCV	6.0	3.4	No separate RI
MPV	6.0	1	No separate RI
CD4 ( $\times 10^9/L$ ) **	5.4	6.2	Separate RI
CD4 percentage**	5.4	6.7	Separate RI

*Z\* = critical value, Z = calculated value, Separate RI are needed only when Z is greater than Z\*; \*\* indicate hematological and CD4 parameters which need partition between male and female ( $Z > Z^*$ )*

**Table 2:** Median, IQR, and 95<sup>th</sup> percentile of reference interval with lower and upper limit 95% CI of hematological and immunological parameters

Parameter		N	Median (IQR)	RI (95th percentile)	Lower Limit 95% CI	Upper Limit 95% CI
WBC ( $\times 10^9/L$ )		967	6.1 (4.8 – 7.7)	3 – 11.2	3 (2.7 – 3.1)	11.2 (10.8 – 11.9)
Neutrophil ( $\times 10^9/L$ )		967	3.2 (2.2 - 4.2)	1.1 – 6.7	1.1 (0.9 - 1.2)	6.7 (6.5 - 6.9)
Lymphocyte ( $\times 10^9/L$ )		967	2.1 (1.7 – 2.6)	1.1 – 4.5	1.1 (1 - 1.2)	4.5 (4.2 - 4.7)
Mixed cells ( $\times 10^9/L$ )		967	0.7 (0.5 - 1)	0.2 – 2.1	0.2 (0.2 - 0.3)	2.1 (2 - 2.1)
Neutrophil %		967	52 (43.5 - 59.4)	27.2 – 71.9	27.2 (25.4 - 29.9)	71.9 (69.6 - 73.1)
Lymphocyte %		967	35.4 (29.4 - 42.1)	19.8 – 57.4	19.8(18.8 - 20.9)	57.4 (56 - 58.1)
Mixed cells %		967	11.3 (8.9 - 15.2)	5.2 – 26.4	5.2 (4.5 - 5.6)	26.4 (25.2 - 28
PLT ( $\times 10^9/L$ )		967	239 (186 - 293)	90 – 399	90 (84 - 94)	399 (381 - 417)
RBC ( $\times 10^{12}/L$ )	Male	534	5.1 (4.8 - 5.5)	4.0 – 6.0	4 (3.9 - 4.2)	6 (6 - 6.2)
	Female	433	4.5 (4.2 - 4.8)	3.5 – 5.6	3.5 (3.4 - 3.6)	5.6 (5.4 - 5.9)
Hgb (g/dl)	Male	534	15.3 (14.2 - 16.5)	12 – 18.9	12 (11.6 - 12.2)	18.9 (18.5 - 19.3)
	Female	433	13.1 (12.1 - 14.3)	10.7 – 17.5	10.7 (10.5 - 11)	17.5 (17 - 18.3)
PCV (%)	Male	534	46.2 (43.6 - 49.2)	35.7 – 55.3	35.7 (34.8 - 36.9)	55.3 (54.2 - 56)
	Female	433	39.9 (37.6 - 43.5)	32.2 – 50.1	32.2 (31 - 33)	50.1 (48.5 - 52.4)
MCV (fl)		967	90.1 (87 - 93)	81 – 100	81 (80.4 - 82)	99.7 (98.7 - 100.7)
MCH (pg)		967	30 (28.1 - 31.7)	25.3 – 34.6	25.3 (25.1 - 25.7)	34.5 (34.3 - 35.2)
MCHC (%)		967	33.9 (30.5 - 35.1)	28.8 – 36.9	28.8 (28.5 - 29)	36.9 (36.6 - 37.1)
RDW (%)		967	13.2 (12.7 - 13.8)	11.6 – 15.4	11.6 (11.4 - 11.8)	15.4 (15.2 - 15.7)
MPV (fl)		967	10 (9.3 - 10.6)	8 – 12.3	8 (7.9 - 8.2)	12.3 (12 - 12.4)
CD4 ( $\times 10^9/L$ )	Male	446	715 (592 - 874)	400 - 1406	400 (370 - 431)	1406 (1250 - 1477)
	Female	338	830 (677 - 1017)	466 - 1523	465 (388 - 494)	1523 (1412 - 1621)
CD4 %	Male	446	36.3 (31.8 - 40.7)	18 - 49.1	18 (15.7 - 20.6)	49.1 (47.9 - 49.9)
	Female	338	40.3 (34.6 - 44.7)	21.3 - 52.9	21.3 (15.9 - 25.6)	52.9 (51.1 - 55.4)

**Table 3:** Comparison of hematological RIs of the current study with previous studies in Africa, USA and test books

Parameters		Current Study	Gondar, Ethiopia (14)	Gojjam, Ethiopia (15)	Kericho, Kenya (31)	Eastern & Southern Africa (6)	Ghana (29)	Southern Tanzania (36)	Uganda (4)	Togo (35)	USA (30)	Rodak's Hematology (34)
WBC ( $\times 10^9/L$ )		3 - 11.2	3.2 - 8.8	3.5 - 11.5	2.8 - 8.2	3.1 - 9.1	3.4 - 9.2	3 - 7.9	2.8 - 8.2	1.9 - 10.1	4.5 - 11	3.6 - 10.6
Neutrophil ( $\times 10^9/L$ )		1.1 - 6.7	1.6 - 5.1	NA	0.9 - 4.7	1.0 - 5.3	1.5 - 5.6	1.1 - 4.7	0.9 - 3.9	0.5 - 5.4	NA	1.7 - 7.5
Lymphocyte ( $\times 10^9/L$ )		1.1 - 4.5	1 - 3.5	NA	1.1 - 3.5	1.2 - 3.5	1.2 - 4.4	1.1 - 3	1.2 - 3.7	1.1 - 4.3	NA	1 - 3.2
Mixed cells ( $\times 10^9/L$ )		0.2 - 2.1	0.2 - 1	NA	NA	NA	NA	0.3 - 1.1	NA	NA	NA	NA
Neutrophil %		27.2 - 71.9	36 - 69	34.3 - 72.1	20-60	25 - 66	32 - 68.1	32 - 69.1	22.2 - 59.3	NA	40 - 70	50 - 70
Lymphocyte %		19.8 - 57.4	22 - 55	17.9 - 53.4	20-60	23 - 59	25.2 - 57.7	20.8 - 56.7	26.7 - 61.2	NA	22 - 44	18 - 42
Mixed cells %		5.2 - 26.4	6 - 13	6 - 23	NA	NA	NA	5.6 - 19.8	NA	NA		NA
PLT ( $\times 10^9/L$ )		90 - 399	128 - 432	113.9 - 372	120 - 411	126 - 438	89 - 380	150 - 395	109 - 384	120 - 443	150 - 350	150 - 450
RBC ( $\times 10^{12}/L$ )	M	4.0-6.0	3.53 - 6.93	3.9 - 6.2	4 - 6.4	4.4 - 6.3	3.79-5.96	4.41 - 6.27	3.8 - 6.1	3.3 - 6.4	4.5 - 5.9	4.2 - 6
	F	3.5 - 5.6	3.45 - 6.25	3.9 - 5.8	3.8 - 5.6	3.7 - 5.6	3.09-5.30	3.84 - 5.59	3.3 - 5.3	3.1 - 6	4 - 5.2	3.8 - 5.2
Hgb (g/dl)	M	12- 18.9	11.5 - 18	13.6 - 19.8	12.2 - 17.7	8.3 - 11.3	11.3-16.4	13.7 - 17.7	11.6 - 17.1	10 - 18.4	13.5 - 17.5	13.5 - 18
	F	10.7 - 17.5	10.9 - 16.9	12 - 18	9.5 - 15.8	5.9 - 10	88-144	11.1 - 15.7	9.8 - 16.2	10.3 - 17.1	12 - 16	12-15
PCV (%)	M	35.7 - 55.3	36.2 - 58.6	45 - 59	35 - 50.8	40 - 50	33.2-50.5	40.2 - 53.7	33.8 - 49.5	28 - 54	41 - 53	40 - 54



	<b>F</b>	32.2 - 50.1	32.1 - 56.6	39 - 55	9.4–45.4	30 - 50	26.4–45.0	36.2 - 46.8	28.3 - 46.8	28 - 47	36 - 46	35 - 49
<b>MCV (fl)</b>		81 - 100	85 - 100	89.5 - 107.5	68.8 - 97.2	68 - 98	72 - 97	77.6 - 98.1	71 - 97	80 - 99	80 - 100	80 - 100
<b>MCH (pg)</b>		25.3- 34.6	NA	28 - 34	22.4 - 33.5	NA	22.6 - 33.5	23.6 - 33.1	23.5 - 33.7	25 - 37	26 - 34	26 - 34
<b>MCHC (%)</b>		28.8 - 36.9	NA	30 - 33.2	32.2–35.3	NA	30.5 - 36.2	30.6 – 34.9	32.5 - 35.3	29 - 41	31 - 37	32 - 36
<b>RDW (%)</b>		11.6 - 15.4	12-18	NA	NA	NA	12.6 - 23	NA	11 - 16.8	NA	11.5–14.5	11.5 - 14.5
<b>MPV (fl)</b>		8 - 12.3	NA	NA	NA	NA	NA	NA	NA	NA	NA	7 - 12

**N.B:** *NA; not applicable (there is no value)*

**Table 4:** Comparison of CD4 and CD4% RIs of the current study with previous studies in Ethiopia, other African countries and Turkey

Parameters		Current Study	Gojjam, Ethiopia (15)	Addis Ababa, Ethiopia (16)	Western Kenya (7)	Central African Republic (20)	Northern Tanzania (21)	Uganda (19)	Gauteng, South Africa (45)	Turkey (46)
CD4 ( $\times 10^9/L$ )	M	400 – 1430	414 – 1474	306 - 1,249	462–1306	391–1,145	362–1,376	503 - 1807	291.2–1278.9	438 - 1,890
	F	466 – 1523	436 – 1695	456 –1,368	440–1602	386–1,355	454–1,485	561 - 2051	288.5–1406.8	394 - 2,234
CD4%	M	18 – 49.1	NA	NA	32–55	23–54	16.5–45.3	27.7 - 56.7	NA	29.91 - 60.12
	F	21.3 – 52.9	NA	NA	29–54	29–55	22.5–48.3	31.6 - 58.0	NA	29.74 - 61.41

